-Hammerstone
Benchmark Maintains Buy on CSX, Lowers Price Target to $35
Benchmark analyst Nathan Martin maintains CSX (NASDAQ:CSX) with a Buy and lowers the price target from $36 to $35.
Venture Capitalist And Political Activist Peter Thiel To Leave Facebook/Meta’s Board, Effectively Immediately
-Hammerstone
Related Posts
Mexico’s Cannabis Market: What Investors And Entrepreneurs Need To Know
Mexico could become the third nation to legalize cannabis after its Supreme Court ruled cannabis use and possession laws were unconstitutional, decriminalizing it in June 2021.
After Nio, More US-listed Chinese Firms May Arrive In Singapore, Says Exchange CEO
Singapore Exchange Ltd. (OTC: SPXCY) expects more listings by U.S.-listed Chinese firms with the exchange trying to woo companies at a time when they are facing greater regulatory and de-listing risks, according to a report by
GSK Announced Blenrep DREAMM-3 Phase III Did Not Meet Primary Endpoint of Progression-free Survival
GSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase III open-label, randomised head-to-head superiority trial of Blenrep (belantamab mafodotin) monotherapy versus pomalidomide in combination with low dose dexamethasone (PomDex) in patients with relapsed or refractory multiple myeloma (RRMM), did not meet its primary endpoint of progression-free survival (PFS).